Publication | Closed Access

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study

UrologySurgical OncologyGenitourinary CancerMedicinePembrolizumab MonotherapyCancer ManagementImmune Checkpoint InhibitorCancer TreatmentPhase 2Oncology